Table 1.
Clinical, biological, pathological, and survival characteristics of the 44 non-muscle-invasive bladder cancers (NMIBC).
| Parameters | Whole Population | No Recurrence | Recurrence | Muscle-Invasive Progression | ||
|---|---|---|---|---|---|---|
| Number of Patients (%) | Number (%) | Number (%) | p-Value * | Number (%) | p-Value ** | |
| Total population | 44 (100.0) | 14 (31.8) | 22 (50.0) | 8 (18.2) | ||
| Age (years) | ||||||
| ≥60 | 34 (77.3) | 10 (29.4) | 16 (47.1) | 0.77 | 8 (23.5) | 0.17 |
| <60 | 10 (22.7) | 4 (40.0) | 6 (60.0) | 0 (0.0) | ||
| Sex | ||||||
| Male | 41 (93.2) | 13 (31.7) | 20 (48.8) | >0.99 | 8 (19.5) | >0.99 |
| Female | 3 (6.8) | 1 (33.3) | 2 (66.7) | 0 (0.0) | ||
| Smoking status | ||||||
| Non-smoker | 19 (43.2) | 4 (21.1) | 12 (63.2) | 0.13 | 3 (15.8) | 0.97 |
| Smoker | 25 (56.8) | 10 (40.0) | 10 (40.0) | 5 (20.0) | ||
| History of NMIBC | ||||||
| No | 24 (54.5) | 11 (45.8) | 10 (41.7) | 0.049 | 3 (12.5) | 0.50 |
| Yes | 20 (45.5) | 3 (15.0) | 12 (60.0) | 5 (25.0) | ||
| Associated pTis | ||||||
| No | 42 (95.4) | 14 (33.3) | 22 (52.4) | NA | 6 (14.3) | 0.030 |
| Yes | 2 (4.6) | 0 (0.0) | 0 (0.0) | 2 (100) | ||
| Grade | ||||||
| Low grade | 20 (45.5) | 9 (45.0) | 10 (50.0) | 0.27 | 1 (5.0) | 0.094 |
| High grade | 24 (54.5) | 5 (20.8) | 12 (50.0) | 7 (29.2) | ||
| Tumor stage | ||||||
| Ta | 30 (68.2) | 10 (33.3) | 18 (60.0) | 0.75 | 2 (6.7) | 0.008 |
| T1 | 14 (31.8) | 4 (28.6) | 4 (28.6) | 6 (42.9) | ||
| FGFR3 status | ||||||
| Mutated | 22 (50.0) | 5 (22.7) | 16 (72.7) | 0.028 | 1 (4.5) | 0.051 |
| Not mutated | 22 (50.0) | 9 (40.9) | 6 (27.3) | 7 (31.8) | ||
| PIK3CA status | ||||||
| Mutated | 7 (15.9) | 4 (57.1) | 2 (28.6) | 0.18 | 1 (14.3) | >0.99 |
| Not mutated | 37 (84.1) | 10 (27.0) | 20 (54.1) | 7 (18.9) | ||
| TERT status a | ||||||
| Mutated | 35 (81.4) | 10 (28.6) | 18 (51.4) | 0.75 | 7 (20.0) | 0.32 |
| Not mutated | 8 (18.6) | 4 (50.0) | 4 (50.0) | 0 (0.0) | ||
* Chi2 test, Chi2 test with Yates’ correction or Fisher test if appropriate (recurrence vs. no recurrence); ** Chi2 test, Chi2 test with Yates’ correction or Fisher test if appropriate (muscle-invasive progression vs. others); In bold: * p-value < 0.05; a Data available for 43 patients; NA: not applicable.